NASDAQ:ONVO - Organovo Stock Price, Forecast & News

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings data on Thursday, November, 7th. The medical research company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The medical research company had revenue of $1.23 million for the quarter, compared to analyst estimates of $0.79 million. Organovo had a negative net margin of 774.47% and a negative return on equity of 74.72%. View Organovo's Earnings History.

Organovo is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Organovo.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Organovo.

News stories about ONVO stock have trended positive on Monday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organovo earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Organovo.

Organovo saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,480,000 shares, a decline of 25.6% from the December 15th total of 1,990,000 shares. Based on an average daily trading volume, of 674,700 shares, the short-interest ratio is currently 2.2 days. Approximately 1.2% of the shares of the stock are short sold. View Organovo's Current Options Chain.

Some companies that are related to Organovo include La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Solid Biosciences (SLDB), LogicBio Therapeutics (LOGC), Windtree Therapeutics (WINT), Dyadic International (DYAI), Applied Genetic Technologies (AGTC), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), Axcella Health (AXLA), Cidara Therapeutics (CDTX), Gamida Cell (GMDA), Polarityte (PTE) and Acorda Therapeutics (ACOR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), Aerojet Rocketdyne (AJRD), NVIDIA (NVDA), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Micron Technology (MU), Exelixis (EXEL), Anavex Life Sciences (AVXL), Novavax (NVAX) and General Electric (GE).

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ONVO stock can currently be purchased for approximately $0.46.

Organovo has a market capitalization of $59.72 million and generates $3.09 million in revenue each year. The medical research company earns $-26,640,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Organovo employs 70 workers across the globe.View Additional Information About Organovo.

The official website for Organovo is http://www.organovo.com/.

Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]